Sign Up NowThis Month's Tiny Gems - March 2018

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)
ChineseInvestors.com (CIIX)
Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)
Earth Science Tech, Inc. (ETST)
FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42)
Hiku Brands Co. Ltd. (DJACF)
Net Element (NASDAQ: NETE)
Pivot Pharmaceuticals Inc. (PVOTF)
Pressure BioSciences Inc. (PBIO)
Standard Lithium Ltd. (TSXV: SLL) (FRA: S5L) (OTCQX: STLHF)
Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF)

 

 

 

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

 

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

 

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

 

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

 

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

 

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

 

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

 

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

 

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO."

 

 

 

ChineseInvestors.com (CIIX)

 

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

 

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

 

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

 

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

 

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

 

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

 

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

 

 

 

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

 

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s "Choom Gang," a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with "choom," the local's term for marijuana. Choom's trademark slogans pivot off another unconventional phrase ("Say Hello to…"), bringing a heady dose of good times and good friends together as the company invites investors to "Say Hello to Choom™" as it lights up the adult recreational cannabis market in Canada.

 

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company's first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom's initial license applications to ensure the company's readiness for legalization of recreational marijuana in Canada mid-summer 2018.

 

True to the company's character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1's revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

 

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic "Aloha" vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

 

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

 

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company's growth strategy. Get ready to "Say Hello" to opportunity, good times and good friends with Choom™.

 

 

 

Earth Science Tech, Inc. (ETST)

 

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company's CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

 

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

 

 

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report's highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

 

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST's medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

 

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company's Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

 

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device's ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

 

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST's International Application for Provisional Patent titled "Cannabidiol Compositions Including Mixtures and Uses Thereof," which was filed on October 8, 2015. Cannabis Thera's R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

 

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

 

Earth Science Tech's products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

 

 

 

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42)

 

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) taps into the primal, unfiltered passion of sports fans from around the world by providing an uncensored social media platform delivered through the FANDOM SPORTS mobile app. As an aggregator, curator and instigator of both company-created and user-generated content, the FANDOM SPORTS app is designed to entertain sports enthusiasts with real-time, interactive content on a mobile only app that offers bragging rights and real-life rewards. True sports addicts will appreciate an app that allows fans to pick a fight or create their own FanFights and rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric "argument engine" measures and scores opinionated dialogue, as well as establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

 

Building on the company's tag line – "Pick a Fight" – the FANDOM SPORTS app provides an always fresh, authentic rush of deeper-than-surface interactive content that resonates with the targeted age demographic of 18-34. Intense sports fans aren't afraid of stepping up to the plate to engage other users by unleashing their opinions within the app's structured debate resolution tool coined "FanFights." Sports-loving fans can explore, gloat, vote, invite friends, create provocative FanFight topics and play to win while inside the FANDOM SPORTS app, which is currently available in the Apple App store and coming to the Google Play store imminently. The company's self-learning algorithm predicts and collects user preferences while building relevant personalized FanFight channels, bringing the concept of competitive, in-your-face conversation to a whole new level of sports entertainment.

 

The FANDOM SPORTS app is free to play (F2P) with in-app purchase and subscription capabilities. The gaming aspect of the ecosystem is built on behavioral economics and delivers multiple revenue streams by maximizing average revenue per daily active user (ARPDAU) and user-generated content (UGC), with select placement of high-impact video and moment-based marketing as part of the brand-sponsored FanFights and in-app offers. The global platform enables applications (either FANDOM SPORTS created or 3rd party apps) to be operated in partnership with leading sports themed brands, leagues, and service providing companies within three verticals – live action, eSports, & fantasy – from around the world by supplying "interactive sports entertainment" to fans. The FANDOM SPORTS platform creates a bullet-proof snapshot of the app's fan base through a Blockchain supported "PlayerCard" in tandem with the "Engagement Score", which doubles as an invaluable acquisition and retention tool for its business operators. FANDOM SPORTS hosted transactions are placed on the distributed ledger, making them immutable and public to verified users interacting within the business ecosystem. Tracking this digital footprint provides extremely valuable metadata generated by users' very dynamic behavior and sports passion.

 

FANDOM SPORTS' Brand and Sponsorship partners are harnessing the affluent sports fans age 18-34 with integrated marketing content and service experience. The moments-based marketing integration will translate through FanCoin redemption, in exchange for items provided by programs established by FANDOM SPORTS and its clients. These programs are a key part of the business model and covers, as an example, the following partners; Sports Leagues, TelCo's service offerings, and Content owners (i.e. FANDOM SPORTS provides new paying customers to the owners of pay-per-view platforms).

 

"Pick A Fight. Talk Trash. Get Rewarded."

 

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

 

The FANDOM SPORTS App is the Company's core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

 

So download the app and bring your crew. Talking trash is better with friends. The more you invite, the more FanCoins you earn.

 

You may also visit the Company's website at www.fandomsportsmedia.com or contact them directly at [email protected]

 

DISCLAIMER:

The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company's control. Some of these risks and uncertainties may be described in the Company's corporate filings (posted at www.sedar.com).

 

The Company has no intention or obligation to update or revise any forward-looking statements due to new information or events.

 

 

 

Hiku Brands Co. Ltd. (DJACF)

 

Headquartered in British Columbia's picturesque Okanagan Valley, Hiku Brands Co. Ltd. (CSE: DOJA) (OTC: DJACF) is a premium cannabis lifestyle brand growing high-quality handcrafted cannabis flower. Hiku's wholly owned subsidiary is a licensed producer of cannabis under the ACMPR that has requested its Pre-Sales License Inspection, the last step prior to receiving a license to sell cannabis under the ACMPR. Hiku's Dominion Facility is a state-of-the-art ACMPR licensed production facility capable of producing approximately 660 kg year of dried cannabis flower. Hiku's second facility, a 22,580 sq ft warehouse, "the FUTURE LAB", is targeting its Phase 1 completion by Q2 2018 and once the facility is fully built-out utilizing an industry leading multi-tier system powered by LED lighting provided by Fluence BioEngineering, Hiku's annual production capacity is expected to be in excess of 5,000 kgs. Hiku was founded by the proven entrepreneurial team that started SAXX Underwear®.

 

On December 21, 2017, Hiku and TS Brandco Holdings Inc. ("Tokyo Smoke") announced that they have entered into a binding Letter of Intent ("LOI") to merger the two companies and create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer with an award-winning lifestyle brand and retail-focused cannabis company. It is anticipated that the combined company resulting from the merger will use the name "Hiku Brands Company Ltd." ("Hiku") to refer to the brand house containing premium cannabis brands DOJA, Tokyo Smoke, and Van der Pop.

 

Hiku recently closed on a $10 million strategic equity investment from Aphria Inc. ("Aphria") (TSX:APH and US OTC: APHQF) to expand their product offering ahead of the recreational market.

 

Upon completion of the merger, Hiku will have a robust cash position of approximately $31 million, which it plans to invest in expanding its cannabis production capacity, growing its retail footprint, and adding select brands to its portfolio through highly strategic and complementary acquisitions.

 

About Tokyo Smoke
Founded in 2015 by Alan and Lorne Gertner, Tokyo Smoke is an award-winning cannabis lifestyle brand that brings sophistication and design to the fast-growing industry. With immersive experiences and design-first, non-dispensary retail spaces selling coffee, cannabis accessories and design products, the brand has six locations in Canada, with plans to expand nationwide. Recently named "Brand of the Year" at the Canadian Cannabis Awards, Tokyo Smoke has showcased excellence in brand storytelling, and has developed an international reputation as the go-to destination for engaging content offerings within the industry. With the acquisition of fellow designer cannabis brand Van der Pop, and by partnering with Aphria Inc. (TSX: APH and US OTC: APHQF) and WeedMD (TSXV: WMD), Tokyo Smoke continues to be the leading Canadian brand in the cannabis space.

 

About Hiku
Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

 

Hiku's wholly owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia's Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

 

 

 

Net Element (NASDAQ: NETE)

 

Net Element (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element's strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte's 2017 Technology Fast 500 ™ and South Florida Business Journal's 2016 fastest growing technology companies.

 

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element's all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

 

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

 

"We believe that we're at the dawn of a new evolution where additional digital payment methods are being introduced," Net Element CEO Oleg Firer, says. "Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element's growing network."

 

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

 

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

 

 

Net Element is ranked No. 418 on Deloitte's 2017 Technology Fast 500™ list of North America's 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company's chief executive officer, Oleg Firer, credits the company's progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

 

"The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment," said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. "These companies are on the cutting edge, and are transforming the way we do business."

 

Net Element's suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

 

Net Element's corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company's mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company's chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

 

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

 

 

 

Pivot Pharmaceuticals Inc. (PVOTF)

 

Pivot Pharmaceuticals Inc. (PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot's recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

 

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

 

Pivot Pharmaceutical's newly created subsidiary, Pivot Green Stream Health Solutions Inc. ("Pivot Green Stream"), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

 

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company's plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

 

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

 

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot's pipeline are cancer supportive care, pain and inflammation, women's sexual dysfunction, dermatology and eye disease.

 

 

 

Pressure BioSciences Inc. (PBIO)

 

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

 

The Company's product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology ("PCT"). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

 

Pressure BioSciences' product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the "Oscars of Innovation"), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. "Cancer Moonshot" program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children's Medical Research Institute (Sydney, Australia), said in a recent interview: "We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more."

 

Momentum is building when it comes to the potential for using the Company's unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences' approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company's technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences' PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

 

The Company's high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

 

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

 

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

 

The Company's UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks' Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences' initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

 

 

 

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF)

 

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is a Canadian-based energy exploration and development company that is building one of the largest portfolios of high quality, domestic U.S. lithium brine assets. Its data and technology driven project development model is grounded in knowledge, opportunity and speed. Standard Lithium is led by an innovative and results-oriented management team with a strong focus on technical skills. The company has acquired several prospective lithium brine projects with known geological values consistent with producing basins, including its primary focus, the Bristol Dry Lake, California brownfield project that is permitted for related mineral production with accompanying world class infrastructure which are expected to contribute to faster, lower cost exploration and commercial development programs.

 

Recent results from a geophysical survey of the 25,000-acre Bristol Lake site suggest a high concentration of lithium-bearing brines are present throughout the company's mineral lease agreement claims. Standard Lithium's strategic partner in the venture, National Chloride Corporation of America, is well established in the region. All necessary infrastructure is on site, which gives Standard Lithium immediate access to conduct exploration brine sampling, lithium extraction, evaporation and processing activities, all within a fast-track project development schedule.

 

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020, at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

 

Standard Lithium's determination to provide battery-grade lithium materials is bolstered by its recently appointed Scientific Advisory Council. These leading lithium extraction scientists and process engineers will oversee and direct the necessary lithium extraction process testing work. In addition to the Bristol Lake Brine Project, the company signed a Memorandum of Understanding in August with an unnamed New York Stock Exchange-listed company on an option for Standard to acquire lithium exploration and productions rights on 30,000 net brine acres overlying the Smackover formation in a region with a history of commercial-scale brine processing. Management believes lithium-bearing brines are likely present in this area. Smackover brines are metal-rich brine anomalies in reservoir rocks along the Gulf Coast from east Texas to Florida known to be a prime lithium resource. This resource may be one of the most promising ones to develop, given that a large-scale brine extraction, processing and reinjection industry is already well established.

 

Recently, Standard Lithium closed a multi-million dollar private placement offering, which allows the company to advance its current projects and pursue strategic acquisitions in the lithium sector. The company is well positioned with significant exploration opportunities featuring low cost production costs, easy transport, proximity to demand, and access to innovative production methodology.

 

 

 

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8)

 

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) is a venture builder that creates, funds and empowers entrepreneurs working in the fields of blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources, and other forms of operational support to help them scale internationally.

 

Victory Square has made multiple early partnerships and investments in the blockchain space. Approximately three years ago the company incubated and invested in BTL Group, which is now a $150 million dollar TSX-listed company offering blockchain solutions across multiple industries with particular focus on the finance, energy and gaming sectors. BTL's showcase product – Interbit – is a blockchain platform that facilitates the rapid development of business applications that dramatically improve efficiency. Some of the world's largest institutions are using Interbit to explore new opportunities on private blockchains.

 

A new social sports betting platform to be developed by Victory Square's wholly owned subsidiary, FansUnite Media Inc. As a social sports data platform, FansUnite relies on robust data to allow members of its community to engage with like-minded individuals by collaborating, discussing, and predicting the winners of sporting events with a free virtual currency. The integration of blockchain technology into FansUnite's social sports data platform could also lead to blockchain initiatives developed by other divisions and subsidiaries of Victory Square.

 

Integral to the FansUnite platform is the introduction of FAN Tokens, an in-game currency purchased with the cryptocurrency Ethereum that token holders can use to place wagers. FansUnite members will be able to earn FAN Tokens through participation in any number of networking effects identified in the company's Bounty program.

 

"Blockchain technology and the inherent security it provides will enable us to push every envelope we can to build the most dynamic and responsive social sports betting platform," said Darius Eghdami, Co-Founder and Chief Executive Officer of FansUnite. "The opportunity to secure data through Blockchain certainly appeals to the accountant in me and we are confident it will become the gold standard among sports betting sites around the world."

 

Company subsidiary Victory Square Health Inc., which serves as the venture arm dedicated to companies focused on the development of solutions in personalized health technologies, has also invested in Personalized Biomarkers Inc. (PBI). PBI develops test kits that reliably predict the expected response to a number of therapies prior to prescription, with an initial focus on diabetes. Within this field, five potential biomarkers have been identified, allowing PBI to enter a $4 billion market opportunity.

 

"We are excited for the opportunity to partner with Personalized Biomarkers as they have correctly identified a massive market opportunity, and have formed an exceptional team of industry leaders," said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. "This is another investment that is fully aligned with our newly created subsidiary, and one we expect to significantly impact the landscape of personalized medicine."

 

A partnership with Insight Diagnostics Inc., also through Victory Square Health, will focus on the development of a personalized diagnostic solution for the improved management and prevention of Type II diabetes.

 

The company's investment in V2 Games, a development and publishing studio of high-quality mobile games, is another example of incubating great ideas. V2 Games is well known for its successful launch of PAC-MAN Bounce and Beast Brawlers, two of the company's releases that are capturing the gaming world by the millions of downloads.

 

In a move designed to strengthen its presence in film and entertainment, Victory Square has acquired a 40 percent equity stake in United Film Fund II, LLC, which is producing three major motion pictures in 2017 and 2018 including "What They Had," starring two-time Academy Award winner Hilary Swank.

 

"This kind of investment in entertainment and film represents a major plank for our Company going forward and we consider ourselves fortunate to have the opportunity to acquire this 40% stake in the Film Fund," said Tejani, who has launched more than 40 startups in 21 countries that employ hundreds of people and generate more than $100 million in annual revenues. "We believe it's another strong initiative in film production for us and our stakeholders," he added.

 

Victory Square has strategically positioned itself in the legal cannabis industry through an investment in Tantalus Labs, a Canadian-based cannabis cultivation company. Tantalus Labs optimizes plant health and sustainable cultivation by using a unique, environmentally controlled greenhouse engineered specifically for growing cannabis. Called a "SunLab," the greenhouse takes 90 percent less electricity, uses filtered rainwater, and cools the growing environment to prevent stagnant moisture, recycling the air every 7 minutes to achieve maximum airflow.

 

Victory Square and its leadership team have seamlessly transitioned from its former identity as Fantasy 6 Sports Inc, a company focused solely on fantasy sports, mobile gaming and immersive sports, to a strategic technology company that creates, funds and successfully executes leading-edge ideas. A long-time technology entrepreneur and advocate of the industry, Tejani received the Person-of-the-Year Award at the 2017 Technology Impact Awards in British Columbia, a hallmark award category that recognizes betterment of the tech industry through leadership and philanthropic or enterprise skills and talents. Tejani has pledged to match up to $1 million in donated funds to be shared by a number of Canadian endeavors aimed at education and child-safe projects.

 

"These are exciting and important steps in the evolution and growth of our Company, and which properly and fully align with our strategic plan focusing on our core competencies in Blockchain Technology, Artificial Intelligence, Gaming, Personalized Health, Film and Virtual, Augmented and Mixed Reality," said Tejani. "We're spurred on by the success we have had in building on our original forays into fantasy sports, mobile gaming and immersive sports. In addition, we are energized by our most recent initiatives in sports, personalized health and entertainment and the confidence being shown by our shareholders in the dynamic direction of the Company."

 

Victory Square Technologies and its management team believe innovation, incubation of excellent ideas and social responsibility are at the core of its growing success.